Table 4.
Associations Between Change in CAF Plasma Concentrations and PFS
| Time Point and CAF | HR* | 95% CI |
|---|---|---|
| Day 8 | ||
| VCP | ||
| IL-8 | 1.48 | 1.02 to 2.16 |
| IL-12 | 0.61 | 0.40 to 0.94 |
| IP-10 | 0.69 | 0.48 to 0.98 |
| MIP-1α | 0.61 | 0.39 to 0.98 |
| CP | ||
| IL-13 | 0.70 | 0.55 to 0.89 |
| IL-15 | 0.76 | 0.60 to 0.98 |
| IL-17† | 0.75 | 0.60 to 0.95 |
| V | ||
| ICAM-1† | 0.53 | 0.30 to 0.96 |
| VEGF† | 1.93 | 1.06 to 3.52 |
| Osteopontin | 0.88 | 0.78 to 1.00 |
| Day 22 | ||
| CP | ||
| MMP-9 | 1.31 | 1.04 to 1.64 |
| Day 43 | ||
| VCP | ||
| IL-8†‡ | 1.56 | 0.98 to 2.48 |
| IFN-ᆇ | 1.27 | 0.98 to 1.60 |
| CP | ||
| IL-15 | 1.74 | 1.04 to 2.90 |
| V | ||
| sIL-2R† | 0.67 | 0.45 to 0.99 |
| IL-5 | 0.83 | 0.71 to 0.96 |
NOTE. HR < 1.0 indicates that increase in CAF level correlates with improved PFS; HR >1.0 = rise in CAF level correlates with worse PFS.
Abbreviations: CAF, cytokine and angiogenic factor; PFS, progression-free survival; HR, hazard ratio; VCP, vandetanib, carboplatin, and paclitaxel; IL, interleukin; IP-10, interferon gamma–induced protein 10; MIP-1α, macrophage inflammatory protein 1α; CP, carboplatin and paclitaxel; V, vandetanib; ICAM-1, intercellular adhesion molecule 1; VEGF, vascular endothelial growth factor; MMP-9, matrix metalloproteinase 9; IFN-α, interferon alfa; sIL-2R, soluble interleukin-2 receptor.
HR indicates relative increase in risk of progression for a patient with a two-fold increase in CAF concentration from baseline compared with a patient with no increase in CAF concentration.
Treatment × change-in-CAF interaction was significant (P < .05).
All associations with PFS were significant (P < .05), except day 43 IL-8 (P = .059) and IFN-α (P = .068), which had significant interactions.